Stay updated on DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial
Sign up to get notified when there's something new on the DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial page.

Latest updates to the DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial page
- Check2 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check10 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check17 days agoChange DetectedDifference0.2%
- Check31 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check46 days agoChange DetectedThe page has been updated to reflect a new version of the study protocol (v2.15.0) and includes the addition of collaborators, while significant details about the study's methodology and eligibility criteria have been removed.SummaryDifference51%
- Check53 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial page.